Erythromycin

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Erythromycin

Examples of brand names: Erythrocin [DE]

ATC code: J01FA01

Main use (for orientation): Bacterial infections

Documented research summary

CBD inhibited experimental erythromycin-probe turnover in rodents; no human drug–drug interaction quantification. Clinical CYP3A/QT precautions are theoretical context, not a drug interaction established by this experiment.

Uncertainties and limitations

Do not extrapolate CBD/THC findings to the other 26 cannabinoids. No general reassurance about safety.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – laboratory and animal studies

Finding ID: B0171

Type of result: Animal experiment / enzymatic probe signal

Observation: Reduced 13C-erythromycin breath response after CBD 10/50 mg/kg in rats; not at 1 mg/kg.

Mechanism: CYP3A probe turnover

Study type: In vivo rat experiment with a nanoemulsion

Context studied: 13C-erythromycin as a metabolic probe; no therapeutic erythromycin exposure/clinical outcome measured.

Clinical interpretation: Experimental laboratory measurement only, not a drug-interaction prediction in humans.

Limitations and uncertainties: Rat, high doses, nanoemulsion; no transfer to patients or other cannabinoids.

Original sources for this finding: Nonlinear Disposition and Metabolic Interactions of Cannabidiol Through CYP3A Inhibition In Vivo in Rats. [BMED33381645]

References and access status

[V2_LABEL_D0291] E.E.S 400 (ERYTHROMYCIN ETHYLSUCCINATE) TABLET [REMEDYREPACK INC.]

Original source / bibliographic reference

Authors: REMEDYREPACK INC.

Year: 2026

Source type: Official US SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[BMED33381645] Nonlinear Disposition and Metabolic Interactions of Cannabidiol Through CYP3A Inhibition In Vivo in Rats.

Original source / bibliographic reference

Authors: Nagao M, Nakano Y, Tajima M, Sugiyama E, Sato VH, Inada M, Sato H.

Year: 2020

Source type: Primary publication; abstract reviewed

DOI: 10.1089/can.2019.0098

PMID: 33381645

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[BMED2550010] Effect of cannabidiol on cytochrome P-450 isozymes.

Original source / bibliographic reference

Authors: Bornheim LM, Correia MA.

Year: 1989

Source type: Primary publication; abstract reviewed

DOI: 10.1016/0006-2952(89)90432-2

PMID: 2550010

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

[BMED2402224] Selective inactivation of mouse liver cytochrome P-450IIIA by cannabidiol.

Original source / bibliographic reference

Authors: Bornheim LM, Correia MA.

Year: 1990

Source type: Primary publication; abstract reviewed

DOI: 10.1016/s0026-895x(25)09483-0

PMID: 2402224

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility